PHASE I-II STUDIES OF ORAL TEGAFUR (FTORAFUR)

[11] BUROKER T, 1979, CANCER, V44, P48, DOI 10.1002/1097-0142(197907)44:1<48::AID-CNCR2820440109>3.0.CO

[12] 2-C

[13] Giller S., 1967, DOKL CHEM, V176, P798

[14] JOHNSON EC, 1973, CANCER CHEMOTH REP 1, V57, P59

[15] LU K, 1975, PHARMACOLOGIST, V17, P202

[16] MACKMAN SANFORD, 1967, CANCER CHEMOTHER REP, V51, P483

[17] SMART CR, 1975, CANCER, V36, P103, DOI 10.1002/1097-0142(197507)36:1<103::AID-CNCR2820360106>3.0.CO

[18] 2-K

[19] TAQUCHI T, 1972, JAP J CANCER CLIN, V18, P550

[20] VALDIVIESO M, 1976, CANCER RES, V36, P1821

[11] BUROKER T, 1979, CANCER, V44, P48, DOI 10.1002/1097-0142(197907)44:1<48::AID-CNCR2820440109>3.0.CO

[12] 2-C

[13] Giller S., 1967, DOKL CHEM, V176, P798

[14] JOHNSON EC, 1973, CANCER CHEMOTH REP 1, V57, P59

[15] LU K, 1975, PHARMACOLOGIST, V17, P202

[16] MACKMAN SANFORD, 1967, CANCER CHEMOTHER REP, V51, P483

[17] SMART CR, 1975, CANCER, V36, P103, DOI 10.1002/1097-0142(197507)36:1<103::AID-CNCR2820360106>3.0.CO

[18] 2-K

[19] TAQUCHI T, 1972, JAP J CANCER CLIN, V18, P550

[20] VALDIVIESO M, 1976, CANCER RES, V36, P1821